Lacosamida

Lacosamide, the active ingredient in Lacosamida, is an Anticonvulsant presented as an oral dosage form for oral use. It is employed to treat partial‑onset seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Lacosamida as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant that targets neuronal hyperexcitability in epilepsy and related seizure disorders. - Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. - Epilepsy (adjunct therapy): provides additional seizure control when other agents are insufficient. - Refractory focal epilepsy: offers an alternative mechanism for patients not responding to standard treatments.

Lacosamide may cause a range of adverse reactions, from mild to serious. Patients should be aware of both common and rare events.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate pain in the head. - Fatigue: unusual tiredness or lack of energy. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe rash: including Stevens‑Johnson syndrome. - Cardiac arrhythmia: prolongation of PR interval on ECG. - Hypersensitivity: anaphylactic reactions or angioedema. - Liver enzyme elevation: significant increase in hepatic transaminases.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Cardiac monitoring: assess PR interval and conduction abnormalities. - Renal function: adjust dosing in severe renal impairment. - Hepatic function: monitor liver enzymes periodically. - Pregnancy counseling: discuss limited data and potential risks. - Concomitant CNS depressants: use with caution due to additive sedation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lacosamide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels. - Phenytoin: can increase risk of cardiac conduction effects. - Strong CYP3A4 inhibitors: may elevate lacosamide concentrations.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate): monitor for additive CNS depression. - Anticoagulants: watch for altered bleeding risk. - Alcohol: increased sedation and dizziness.